Trends in Gleason Score: Concordance Between Biopsy and Prostatectomy over 15 Years

Ayyathurai, Rajinikanth; Manoharan, Murugesan; Soloway, Cynthia T.; Civantos, Francisco; Soloway, Mark S.

doi:10.1016/j.urology.2007.10.022

Cited by 103 publications

(75 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 The Gleason score (GS) of prostate biopsy specimens diagnosed by pathologists is of crucial importance to assess aggressiveness of PCa; however, several studies revealed discrepancies of GS between biopsy specimens and the corresponding radical prostatectomy specimens. 13 This leads to a large number of overtreatment of indolent PCa. Therefore, development of effective tools for diagnosis and assessment of PCa is quite urgent.…”

Section: Introductionmentioning

confidence: 99%

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL

Chen

Rong

Shao

et al. 2017

IJN

View full text Add to dashboard Cite

The surface-enhanced Raman spectroscopy (SERS) of blood serum was investigated to differentiate between prostate cancer (PCa) and benign prostatic hyperplasia (BPH) in males with a prostate-specific antigen level of 4–10 ng/mL, so as to reduce unnecessary biopsies. A total of 240 SERS spectra from blood serum were acquired from 40 PCa subjects and 40 BPH subjects who had all received prostate biopsies and were given a pathological diagnosis. Multivariate statistical techniques, including principal component analysis (PCA) and linear discriminant analysis (LDA) diagnostic algorithms, were used to analyze the spectra data of serum from patients in control (CTR), PCa and BPH groups; results offered a sensitivity of 97.5%, a specificity of 100.0%, a precision of 100.0% and an accuracy of 99.2% for CTR; a sensitivity of 90.0%, a specificity of 97.5%, a precision of 94.7% and an accuracy of 98.3% for BPH; a sensitivity of 95.0%, a specificity of 93.8%, a precision of 88.4% and an accuracy of 94.2% for PCa. Similarly, this technique can significantly differentiate low- and high-risk PCa with an accuracy of 92.3%, a specificity of 95% and a sensitivity of 89.5%. The results suggest that analyzing blood serum using SERS combined with PCA–LDA diagnostic algorithms is a promising clinical tool for PCa diagnosis and assessment.

show abstract

Section: Introductionmentioning

confidence: 99%

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL

Chen

Rong

Shao

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…Because of low diagnostic accuracy of TRUS, many doctors prefer systematic biopsies for detection of prostate cancer (2). However, about 25% to 35% of cancers are missed on first systematic biopsy (3,4) and the Gleason score, which characterizes the malignant potential of prostate cancer, is commonly underestimated (5). In addition, attempts to improve prostate cancer detection by intensifying the biopsy technique have failed and seem to increase the risk of complications (6).…”

Section: Introductionmentioning

confidence: 99%

In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548

Kähkönen

Jambor

Kemppainen

et al. 2013

Clinical Cancer Research

178

164

View full text Add to dashboard Cite

Purpose: A novel [68 Ga]-labeled DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-ValGly-His-Sta-Leu-NH 2 peptide (BAY86-7548) having high affinity to bombesin receptor subtype II to detect primary and metastatic prostate carcinoma using positron emission tomography/computed tomography (PET/CT) was synthesized and evaluated for prostate cancer. Experimental Design: In this first human study with BAY86-7548, 14 men scheduled for radical prostatectomy (n ¼ 11) or with biochemical recurrence after surgery or hormonal therapy (n ¼ 3) were enrolled. The patients received an intravenous injection of BAY86-7548 followed by over 60-minute dynamic imaging of prostate gland (n ¼ 10) and/or subsequent whole-body imaging (n ¼ 14). The visual assessment of PET/CT images included evaluation of intraprostatic (12 subsextants) and pelvic nodal uptake of BAY86-7548 in 11 surgical patients and detection of potential metastatic foci in all patients. In patients with biochemical recurrence, results were compared with those of eitherWe found a sensitivity, specificity, and accuracy of 88%, 81% and 83%, respectively, for detection of primary PCa and sensitivity of 70% for metastatic lymph nodes using histology as gold standard. BAY86-7548 correctly detected local recurrence in prostate bed and showed nodal relapse in accordance with

show abstract

“…Bununla beraber biyopsi ve prostatektomi örnekleri ile Gleason değeri arasında tam bir uyum olmadığı çeşitli serilerde belirtilmiştir (9). Biyopsi ve radikal prostatektomiden elde edilen uyumsuzluk; örnekleri farklı patologların değerlendirmesi, Gleason skorunun 6-8 gibi dar bir aralıkta tanımlanabilmesi gibi nedenlere bağlanmıştır (10,11).…”

Section: Discussionunclassified

Is There a Concordance Between the Gleason Scores of Needle Biopsy and Radical Prostatectomy Specimens in Prostatic Carsinoma?

Özgör¹,

Küçüktopçu²,

Şahan³

et al. 2016

Haseki

View full text Add to dashboard Cite

ÖzAmaç: Prostat biyopsi ve radikal prostatektomi örneklerinin Gleason skorları (GS) arasındaki uyumu değerlendirmektir. Yöntemler: Haseki Eğitim ve Araştırma Hastanesi, ÜrolojiKliniği'nde 2008 ile 2012 yılları arasında prostat kanseri ön tanısıyla 1135 hastaya prostat biyopsisi yapıldı. Bu hastalardan 366'sına prostat kanseri tanısı konuldu. Radikal prostatektomi operasyonu 73 hastaya yapıldı ve bu hastaların biyopsi ve prostatektomi örneklerinden elde edilen GS'si karşılaştırıldı. Hastalar D'amico sınıflamasına göre düşük, orta, yüksek risk olmak üzere 3 sınıfa ayrıldı.Bulgular:Hastaların yaş ortalaması 64,2±6,1 (aralık: 54-73) idi. Hastaların serum prostat spesifik antijen seviyeleri ortalaması 20,34 ng/mL olarak bulundu. Hastaların core biyopsi sayısı ortalaması 12±0,58 idi. Hastaların %65,7'sinde biyopsi sonrası ve radikal prostatektomi sonrası GS'nin değerlerinin uyumlu olduğu görüldü ve istatiksel olarak anlamlı olduğu saptandı (p<0,01). Biyopsi sonrası yapılan değerlendirmede düşük risk grubunda olan 40 hastanın radikal prostatektomi sonrasında gerçekte sekizinin (%20) orta risk grubunda, birinin de (%2,5) yüksek risk grubunda olduğu görüldü.Sonuç:Hastalara doğru tedavi yaklaşımını belirlemede biyopsi ve prostatektomi sonrasındaki GS arasındaki uyum önemlidir.Anahtar Sözcükler: Adenokanser, radikal prostatektomi, transrektal biyopsi Abs tractAim:To evaluate the concordance between the Gleason Scores (GS) of prostate biopsy and radical prostatectomy specimens. Methods:Prostate biopsy was performed in 1135 patients with the suspicion of prostate cancer in our clinic between 2008 and 2012. A total of 366 patients were diagnosed with prostate cancer. Radical prostatectomy was performed in 73 of these patients and GS of pathology specimens were included in this study for comparison. The patients were divided into three groups (low intermediate-and high-risk patients) according to the D'amico risk classification for prostate cancer.Results:The median age of the patients was 64.2±6.1 years (54-73). The mean prostate specific antigen level was 20.34 ng/mL and the mean biopsy core number was 12±0.58. A statistically significant concordance was detected between the GS of biopsy specimens and radical prostatectomy materials in 65.7% of patients (p<0.01). There were 40 patients in the low-risk group, however, 8 (20%) of them were identified to be intermediate-risk patients and one (2.5%) was found to be a high-risk patient after radical prostatectomy. Conclusion:Concordance between the GS of prostate biopsy and radical prostatectomy materials are important for selection of the appropriate treatment.

show abstract

Trends in Gleason Score: Concordance Between Biopsy and Prostatectomy over 15 Years

Cited by 103 publications

References 25 publications

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL

In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548

Is There a Concordance Between the Gleason Scores of Needle Biopsy and Radical Prostatectomy Specimens in Prostatic Carsinoma?

Contact Info

Product

Resources

About

Trends in Gleason Score: Concordance Between Biopsy and Prostatectomy over 15 Years

Cited by 103 publications

References 25 publications

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4&ndash;10 ng/mL

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4&ndash;10 ng/mL

In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548

Is There a Concordance Between the Gleason Scores of Needle Biopsy and Radical Prostatectomy Specimens in Prostatic Carsinoma?

Contact Info

Product

Resources

About

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL